|
J Biol Chem, Vol. 274, Issue 37, 26461-26468, September 10, 1999
Effect of Loss of P2Y2 Receptor Gene Expression on
Nucleotide Regulation of Murine Epithelial Cl
Transport*
Victoria L.
Cressman,
Eduardo
Lazarowski,
László
Homolya,
Richard C.
Boucher,
Beverly H.
Koller, and
Barbara R.
Grubb
From the Cystic Fibrosis/Pulmonary Research and Treatment Center,
The University of North Carolina,
Chapel Hill, North Carolina 27599
 |
ABSTRACT |
Extracellular nucleotides are believed to be
important regulators of ion transport in epithelial tissues as a result
of their ability to activate cell surface receptors. Although numerous receptors that bind nucleotides have been identified, the complexity of
this receptor family, combined with the lack of pharmacological agents
specific for these receptors, has made the assignment of particular
receptors and ligands to physiological responses difficult. Because ATP
and UTP appear equipotent and equieffective in regulating ion transport
in many epithelia, we tested the hypothesis that the
P2Y2 receptor (P2Y2-R) subtype mediates
these responses in mouse epithelia, with gene targeting techniques.
Mice with the P2Y2-R locus targeted
and inactivated (P2Y2-R( / )) were generated, airways
(trachea), gallbladder, and intestines (jejunum) excised, and
Cl secretory responses to luminal nucleotide additions
measured in Ussing chambers. Comparison of P2Y2-R(+/+) with
P2Y2-R( / ) mice revealed that P2Y2-R
mediated most (>85-95%) nucleotide-stimulated Cl
secretion in trachea, about 50% of nucleotide responses in the gallbladder, and none of the responses in the jejunum. Dose-effect relationships for nucleotides in tissues from P2Y2-R( / )
mice suggest that the P2Y6-R regulates ion transport in
gallbladder and to a lesser extent trachea, whereas P2Y4
and/or unidentified receptor(s) regulate ion transport in jejunum. We
conclude that the P2Y2 receptor is the dominant P2Y
purinoceptor that regulates airway epithelial ion transport, whereas
other P2Y receptor subtypes are relatively more important in other
nonrespiratory epithelia.
 |
INTRODUCTION |
Metabotropic (G protein-coupled) P2Y receptors are expressed in
epithelia and regulate epithelial ion transport and, consequently, have
become potential targets for drug therapy of diseases that reflect
abnormal epithelial ion transport (1). Of particular interest in this
context is cystic fibrosis
(CF),1 a disease that
reflects widespread defects in epithelial ion transport due to
mutations in the cystic fibrosis transmembrane conductance regulator
(CFTR) (2). However, the spectrum of epithelia affected by this disease
(e.g. airway, gallbladder, and intestine), the diversity of
P2Y receptor subtypes (3), and the absence of selective reagents to
define which P2Y receptor subtypes regulate ion transport have made it
difficult to initiate therapeutic programs to target specific
purinoceptors in these tissues.
The strongest evidence for a role for P2 receptors in the regulation of
ion transport emanates from studies of airway epithelia. Recent reports
indicate that extracellular triphosphate nucleotides regulate many of
the airway ion transport paths, including slowing Na+
absorption (4) and stimulating Cl and K+
secretion (5, 6). Pharmacological studies in the human airway
epithelial cell line CF/T43 have demonstrated that UTP and ATP are
equipotent and cross-desensitize in promoting phospholipase C activity,
leading to the hypothesis that the P2Y2 receptor
(P2Y2-R) is the dominant receptor mediating these responses
(7, 8). However, it is difficult to distinguish whether the actions of ATP and UTP on ion transport are mediated by a single
purine/pyrimidine-sensitive receptor (e.g. P2Y2)
and/or a combination of other recently cloned P2Y receptors that are
potently activated by ATP (e.g. P2Y1 (9, 10),
P2Y11 (11), or P2X (3, 12-14)), and UTP (e.g.
P2Y4 (15, 16)).
Studies of the P2Y receptor subtypes and regulation of ion transport in
the gastrointestinal system are more limited. Data from the murine
gallbladder suggest that both ATP and UTP are active in regulating
Cl and HCO3 secretion
(17, 18), suggesting that the P2Y2-R may be the major P2Y-R
subtype regulating ion transport in this tissue. Early studies of
freshly excised rat jejunum reported regulation of ion transport by ATP
but not UTP (19). More recent studies of triphosphate and diphosphate
nucleotides in cell lines derived from the human intestine
(e.g. CaCo2 cells) suggest that ATP, UTP, and UDP regulate
enterocyte Cl secretory rates (20).
We report here the use of a genetic approach (21) combined with
traditional pharmacological methodologies to define the relative role
of purinoceptors in the regulation of ion transport in epithelial
tissues. Based on the reports of the actions of ATP and UTP in the
epithelia described above, a first approach was to target a single
receptor that could transduce responses to ATP and UTP equipotently.
The P2Y2-R exhibits this pharmacology, and, consequently,
mice were generated with inactivated
P2Y2-R genes using the homologous
recombination technique (21). Because triphosphate nucleotide effects
on Cl and water secretion are projected as the major
therapeutic actions of these agents in epithelial diseases such as CF
(5, 22), characterization of these mice focused on the role of the
P2Y2 receptor in mediating epithelial Cl
secretory responses. In a companion paper (23), the role of P2Y2 receptor in inositol phosphate formation and
intracellular Ca2+ mobilization in tracheas and other
tissues were characterized.
 |
EXPERIMENTAL PROCEDURES |
Mice Used for Phenotypic Characterization--
Adult mice (wild
type and P2Y2-R( / )) of both sexes were used in this
investigation. All animals were bred and raised at the University of
North Carolina. The mean body mass of the normal animals (32.4 ± 1.8 g, n = 20) was not significantly different from the mean body mass of the littermate P2Y2-R( / )
mice (34 ± 1.9 g, n = 21). All mice were
allowed food and water ad libitum until euthanized.
Mice were euthanized with 100% CO2, and the tracheas,
intestine, and gallbladders were quickly excised. The trachea was
dissected free of vessels and connective tissue, split longitudinally
along the posterior surface, and mounted in Ussing chambers (24). The
gallbladder was opened, irrigated to remove bile, and mounted as a flat
sheet in an Ussing chamber. Because of the fragility of gallbladders, a
cellulose mesh was placed over the aperture of the Ussing chamber
(serosal side only) to prevent the tissue from falling through the
aperture. Both tissues were mounted on Ussing chambers having an
aperture surface area of 0.025 cm2. The techniques for
mounting the intestinal tissue (0.25-cm2 aperture Ussing
chamber) have been previously described (25). Parafilm "O" rings
were placed on both sides of the tissues to reduce edge damage.
Bioelectric Measurements--
Electrical measurements of tissues
were made under short circuit (Isc) conditions
as previously reported (24, 26). Tissues were bathed bilaterally in
gassed (95% O2, 5% CO2) Krebs bicarbonated Ringer solution having the following composition: 140 mM
Na+, 120 mM Cl , 5.2 mM K+, 1.2 mM Mg2+, 1.2 mM Ca2+, 2.4 mM
HPO42 , 0.4 mM
H2PO4 , 25 mM
HCO3 , and 5 mM glucose.
Amiloride (10 4 M; Sigma) was added to the
luminal side of all tracheas to block Na+ absorption, which
allows Cl secretory responses to agonists to be studied
(24). Since the gallbladder and jejunum were unresponsive to amiloride,
this drug was omitted from the protocols involving these tissues.
Tissues were allowed to stabilize for 30 min before the first
measurements were made or drugs added. Short circuit
(Isc) was continuously recorded and resistance
calculated by Ohm's law by measuring the Isc
change in response to a 1-mV constant voltage pulse (26). All additions
were to the luminal bath.
Protocols--
For the dose-response studies, each dose was
added cumulatively to the luminal surface of the tissue. When the
tissue responded to the agonist, the response was immediate. After the
response had peaked and/or stabilized (usually 2-3 min), the next dose was added. The response to the added agonist was determined as a change
in the Isc from the basal or previous dose
level. For studies of the P2Y1 antagonist A3P5P in jejunum,
tissues were pretreated with A3P5P (10 4 M) in
the luminal solution prior to nucleotide additions.
Materials--
ATP and UTP were purchased from Amersham
Pharmacia Biotech (Uppsala, Sweden), A3P5P was from Sigma,
, -methylene ATP ( , -meATP), 2-methylthio-ATP (2-MeSATP), and
2-methylthio-ADP (2-MeSADP) from RBI (Natick, MA), and UDP and
adenosine from Roche Molecular Biochemicals. Because UTP could
potentially contaminate commercial preparations of UDP, and to prevent
formation of UTP from UDP via nucleoside diphosphokinase and
endogenously released ATP, hexokinase (10 units/ml) and glucose (25 mM) were present in all UDP stocks, and the purity of UDP
was monitored by high pressure liquid chromatography (27).
Data Analysis/Statistics--
For all tissues, data are
expressed in terms of Isc. This
Isc response is generated primarily by
Cl secretion and to a lesser extent
HCO3
secretion.2 Therefore, here
the Isc is often referred to as
Cl secretion. Apparent EC50 values represent
the concentration of agonist that generated either 50% of the maximal
response or, if saturation was not achieved, 50% of the response to
10 4 M. All data are expressed as mean ± S.E. Statistical analyses were performed with nonpaired Student's
t tests.
 |
RESULTS |
Tracheal Epithelium
Characterization of Wild Type (+/+) Freshly Excised Murine Tracheal
Responses to Nucleotides--
The cumulative dose-effect relationships
for six different nucleotides which are known to be agonists at
different P2 receptors versus tracheal
Cl secretion rates ( Isc) are
shown in Fig. 1A; ATP and UTP
were nearly equipotent and were the most effective agonists for the induction of Cl secretion. Table
I shows that in addition to ATP and UTP,
only UDP elicited a saturable Cl secretory response
within the micromolar concentration range (<10 4
M) (27). The maximal effect of UDP was small (~20%)
compared with ATP/UTP responses. The weak effect of 2-MeSADP or
2-MeSATP suggested that it was unlikely that ATP responses were
primarily mediated by a P2Y1 receptor. Adenosine was also
relatively ineffective (~15% of maximal ATP response;
Isc = 36 ± 11 µA·cm2 at
10 4 M, n = 5). These data
suggest that the P2Y2 receptor may be the dominant receptor
in airway epithelia of the murine trachea but that a receptor that is
activated by UDP (e.g. P2Y6) is also expressed in this tissue.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Mouse tracheas: wild type
(P2Y2-R(+/+)). A,
Isc dose response to the indicated nucleotides.
Data are means ± S.E., n = 6 at each dose.
B, desensitization of tracheal ATP responses.
Isc responses to 10 4 M
ATP were measured in tracheas that were pretreated with no other
nucleotide (None, n = 7) or that were
pretreated with 10 4 M UTP (n = 4), UDP (n = 3), or 2-MeSATP (n = 3).
C, desensitization to UTP responses.
Isc responses to 10 4 M
UTP were measured in tracheas that were pretreated with no other
nucleotide (None, n = 7) or that were
pretreated with 10 4 M ATP (n = 4), UDP (n = 3), or 2-MeSATP (n = 2).
D, desensitization to UDP responses.
Isc responses to 10 4 M
UDP were measured in tracheas that were pretreated with no other
nucleotide (None, n = 6) or that were
pretreated with 10 4 M ATP (n = 3), UTP (n = 3), or 2-MeSATP (n = 3).
p 0.05. Data in all bar graphs
are means ± S.E.
|
|
As a second approach to identify individual P2 receptors in wild type
mouse trachea, cross-desensitization studies were performed. The
initial analysis of the interactions suggests that there is cross-desensitization between ATP and UTP; the ATP response was abolished by UTP pretreatment (Fig. 1B), and the UTP
response was abolished by ATP pretreatment (Fig. 1C),
consistent with interaction of both ligands at a single
(P2Y2) receptor.
However, this interpretation was complicated by the observation that
both agonists produced large maximal responses (>200 µA·cm 2), suggesting that the failure to observe a
second response could reflect a ceiling effect and/or desensitization
of other effectors in the Cl secretory pathway. This
possibility was supported by the observations that (i) UDP responses
also were abolished by ATP or UTP pretreatment (Fig. 1D) and
(ii) the actions of the muscarinic receptor agonist carbachol were
reduced after exposure of the tissue to either ATP or UTP as
pretreatment ( carbachol (10 4 M) naive = 62 ± 3.3 µA·cm 2; carbachol
(10 4 M) post-ATP (10 4
M) = 19 ± 5 µA·cm 2). Thus, it
is not clear whether the reduced effects of UTP post-ATP indicate
desensitization of a common receptor for these nucleotides (e.g. P2Y2) or whether activation of, for
example, a uridine-selective receptor (e.g. P2Y4
or P2Y6) is masked by the ceiling effect of ATP acting on
an ATP-selective receptor (e.g. P2Y11 or P2X
receptor). Moreover, since P2Y4, P2Y6, and
P2Y11 receptors are not pharmacologically defined in the
mouse, we cannot rule out the possibility that either of these
receptors is activated by ATP, UTP, and UDP. The modest inhibition of
the ATP response by 2-MeSATP pretreatment (Fig. 1B) without
any effect on UTP or UDP responses (Fig.
2, C and D) raises
the possibility of a low level of functional expression of a
P2Y1 receptor in murine trachea.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Mouse tracheas:
P2Y2-R( / ). A,
Isc dose response to the indicated nucleotides.
Data are means ± S.E., n = 6 at each dose.
B, desensitization to ATP responses.
Isc responses to 10 4 M
ATP were measured in tracheas that were pretreated with no other
nucleotide (None, n = 10) or that were
pretreated with 10 4 M UTP (n = 4), UDP (n = 3), or 2-MeSATP (n = 3).
C, desensitization to UTP responses.
Isc responses to 10 4 M
UTP were measured in tracheas that were pretreated with no other
nucleotide (None, n = 7) or that were
pretreated with 10 4 M ATP (n = 3), UDP (n = 3), or 2-MeSATP (n = 3).
D, desensitization to UDP responses.
Isc responses to 10 4 M
UDP were measured in tracheas that were pretreated with no other
nucleotide (None, n = 6) or that were
pretreated with 10 4 M ATP (n = 3), UTP (n = 3), or 2-MeSATP (n = 3).
Data in all bar graphs are means ± S.E.
|
|
In summary, it is difficult from the above data to distinguish whether
a single receptor, e.g. P2Y2, or a mixture of
receptors accounted for all of the effects observed with the six
agonists tested. In an attempt to resolve these issues, a comparable
characterization of the nucleotide responses of
P2Y2-R( / ) mouse tracheas was performed.
Characterization of P2Y2-R( / ) Freshly Excised
Tracheas--
Fig. 2A shows the cumulative dose-effect
relationships for the six nucleotides versus
Cl secretion ( Isc) for the
tracheas from P2Y2-R( / ) mice plotted on the same scale
as for wild type (+/+) mice. There were major (more than 85-95%)
reductions in the Cl secretory responses to UTP and ATP
at all concentrations tested. Further, there were major reductions in
the magnitude of the responses to , -meATP, 2-MeSATP, and 2-MeSADP
(Table I), indicating that these P2X and P2Y1 receptor
agonists (or contaminants), at high concentrations, also interact with
the P2Y2 receptor. No reduction in Cl
secretory responses to UDP was observed relative to wild type, P2Y2-R(+/+) mice (Table I).
To verify that the P2Y2-R disruption did not
affect the Cl secretory capacity of the trachea, we
compared responses to carbachol. Carbachol (10 4
M) was equieffective in P2Y2-R(+/+) (62 ± 3 µA·cm 2) and P2Y2-R( / ) mice (63 ± 2 µA·cm 2), suggesting that the Cl
secretory capacity of the trachea was not decreased by targeting the
P2Y2 locus (n = 4, both groups).
The calculated EC50 values, the magnitude of the maximal
response, and the percentage reduction in the maximal responses for the
P2Y2-R( / ) mice as compared with wild type mice (Table
I) clearly indicate that the P2Y2 receptor is the dominant
receptor in the murine trachea that transduces the administration of
triphosphate nucleotides to the tracheal epithelial surface into
Cl secretory responses.
A variety of protocols were employed in an attempt to identify the
residual receptors expressed in the P2Y2-R( / ) mouse
trachea. These protocols were in general difficult because of the small magnitude of the Cl secretory responses mediated by
residual receptors and the failure of most agonists to reach saturating
concentrations within the submillimolar range.
UDP responses in the tracheal preparations were not affected by the
P2Y2 receptor disruption (Table I), suggesting that a functional P2Y6 receptor is expressed in this tissue. Since
P2Y6 receptors are activated, although weakly, by ADP (28),
a portion of the small residual ATP effect could reflect extracellular
conversion of ATP to ADP (29). However, although ATP inhibits
UDP-evoked responses (Fig. 2D), UDP does not affect
subsequent responses to ATP (Fig. 2B). This finding suggests
that ATP could affect UDP responses by a different mechanism,
e.g. ATP-dependent removal of UDP by
ectonucleoside diphosphokinase (27).
A small residual effect of UTP was also observed in the
P2Y2-R / tracheal epithelia (Fig. 2 and Table I), which
was mostly inhibited by pretreatment with UDP. This residual effect of
UTP could reflect either extracellular conversion of UTP to UDP or direct activation of murine P2Y6 receptors by UTP. The
attenuation of UDP-promoted responses by UTP supports either of these possibilities.
Finally, the residual ATP effects were very small. The equipotency and
equieffectiveness of 2-MeSADP (and 2-MeSATP) with ATP (Table I) suggest
that this small residual effect may reflect a P2Y1-R-like activity.
Gallbladder
Characterization of Nucleotide- stimulated Cl
Secretion in Wild Type (P2Y2-R(+/+)) Freshly Excised
Gallbladders--
We next tested for the effect of nucleotides on the
freshly excised murine gallbladder (Fig.
3). These data differ from the freshly
excised trachea in one striking respect, i.e. UDP was virtually equieffective and equipotent with ATP and UTP in initiating a
secretory response ( Isc) in this tissue (Fig.
3A, Table II). 2-MeSADP
induced a small response (~40% of ATP response), which was only
attained at high micromolar concentrations. 2-MeSATP and , -meATP
were entirely without effect in this tissue (Table II). Unlike the
trachea, adenosine was completely ineffective ( Isc = 3.9 ± 2.8 µA·cm2
at 10 4 M, n = 3).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Mouse gallbladders: wild type
(P2Y2-R(+/+)). A,
Isc dose response to the indicated nucleotides.
Data are means ± S.E., n = 6 at each dose.
B, desensitization to ATP responses.
Isc responses to 10 4 M
ATP were measured in gallbladders that were pretreated with no other
nucleotide (None, n = 7) or that were
pretreated with 10 4 M UTP (n = 4), UDP (n = 3), or 2-MeSATP (n = 3).
C, desensitization to UTP responses.
Isc responses to 10 4 M
UTP were measured in gallbladders that were pretreated with no other
nucleotide (None, n = 6) or that were
pretreated with 10 4 M ATP (n = 5), UDP (n = 3), or 2-MeSATP (n = 2).
D, desensitization to UDP responses.
Isc responses to 10 4 M
UDP were measured in gallbladders that were pretreated with no other
nucleotide (None, n = 6) or that were
pretreated with 10 4 M ATP (n = 3), UTP (n = 3), or 2-MeSATP (n = 3).
*, p 0.05 compared with result with no nucleotide
pretreatment (None). Data in all bar graphs are means ± S.E.
|
|
Fig. 3, B-D, displays cross-desensitization
protocols. UTP but not UDP partially blocked the subsequent response to
ATP, and ATP largely attenuated the subsequent response to UTP but not to UDP, consistent with an interaction of ATP and UTP at a
P2Y2 receptor. UDP attenuated the subsequent response to
UTP but not to ATP (Fig. 3, B and C), and UTP
blocked the subsequent response to UDP (Fig. 3D).
In summary, the data indicate the possible expression of a
P2Y2 and a P2Y6 receptor in the murine gall
bladder epithelium. To test this hypothesis more rigorously, we
characterized the effect of nucleotides on the gallbladder epithelial
cells from the P2Y2-R( / ) mouse.
Characterization of P2Y2-R( / ) Freshly Excised
Gallbladder (Fig. 4)--
Disruption of
the P2Y2-R gene in the gallbladder
revealed that the responses to ATP were virtually abolished in the
P2Y2-R( / ) gallbladders. In contrast, the effect of UTP
was only partially reduced (30%) in the P2Y2-R( / )
gallbladder cells relative to the wild type cells, whereas the UDP
responses were not affected by the P2Y2-R disruption (Table
II).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 4.
Mouse gallbladders:
P2Y2-R( / ). A,
Isc dose response to the indicated nucleotides.
Data are means ± S.E., n = 6 at each dose.
B, desensitization to ATP responses.
Isc responses to 10 4 M
ATP were measured in gallbladders that were pretreated with no other
nucleotide (None, n = 7) or that were
pretreated with 10 4 M UTP (n = 5), UDP (n = 3), or 2-MeSATP (n = 3).
C, desensitization to UTP responses.
Isc responses to 10 4 M
UTP were measured in gallbladders that were pretreated with no other
nucleotide (None, n = 7) or that were
pretreated with 10 4 M ATP (n = 6), UDP (n = 3), or 2-MeSATP (n = 2).
D, desensitization to UDP responses.
Isc responses to 10 4 M
UDP were measured in gallbladders that were pretreated with no other
nucleotide (None, n = 8) or that were
pretreated with 10 4 M ATP (n = 3), UTP (n = 3), or 2-MeSATP (n = 3).
*, p 0.05 compared with pretreatment with no other
nucleotide. Data in all bar graphs are means ± S.E.
|
|
Studies of interactions with the residual ATP responses were not
informative because of the very small magnitude of these residual
responses (Fig. 4). With respect to UTP, the relatively large (70% of
wild type) residual UTP response was blocked by UDP but not ATP (or
2-MeSATP) pretreatment (Fig. 4C). Similarly, the persistent
UDP response was inhibited by UTP but not adenine nucleotide
pre-treatment (Fig. 4D). These data suggest that a common
receptor transduces the P2Y2-R( / ) gallbladder UDP/UTP response. The P2Y6-R is a candidate for this function.
Jejunum
Effect of Nucleotides on Cl Secretory Responses in
Normal (P2Y2-R(+/+)) Jejuna--
The luminal dose-response
curve describing the actions of ATP, UTP, ADP, and UDP on freshly
excised normal mouse jejuna are shown in Fig.
5A. Several points deserve
comment. First, unlike the tracheal and gallbladder preparations,
approximately 25-30% of the normal jejunal preparations failed to
respond to any nucleotide. These preparations were viable, since they
had a normal response to forskolin. The nonresponding preparations were
omitted from the analysis. Second, the dose-effect relationships for
all the effective agonists were somewhat shifted to the right (see
Table III for EC50 values) as
compared with the activities in the gallbladder and trachea. Third, as
in the other tissues, ATP and UTP were approximately equieffective and
equipotent agonists at the luminal jejunum surface. Fourth, uniquely in
the jejunum, ADP was also nearly as effective and potent as ATP and
UTP. In contrast to the gallbladder and trachea, UDP appeared to be
weak and relatively ineffective. Adenosine (10 4
M) was ineffective ( Isc = 9 ± 5 µA·cm2, n = 3) in jejunum. Based
simply on the agonist dose-effect curves, it seems reasonable to
postulate that both P2Y2 (ATP/UTP)-like and perhaps
P2Y1-like (ADP) activities are expressed in jejuna.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
Mouse jejuna: wild type
P2Y2-R(+/+). A, Isc
dose response to the indicated nucleotides. n = 6 or
more at each dose. B, desensitization study of response to
ATP after treating tissue with 10 4 M UTP
(n = 5). None refers to ATP response without
pretreatment with another nucleotide (n = 6).
p 0.05. C, desensitization study of
response to UTP after pretreating the tissue with ATP
(10 4 M). n = 8. None, n = 8. *, p 0.05.
|
|
Cross-desensitization experiments (Fig. 5B) suggested that
UTP desensitized the subsequent ATP responses and that the converse was
also true, consistent with the possibility that P2Y2
receptors transduce ATP/UTP responses. However, the ceiling effect
described earlier may be an equally likely alternative explanation for
these results.
Effect of Nucleotides on Cl Secretory Response in
P2Y2-R( / ) Mouse Jejuna--
In contrast to the data
from the P2Y2-R( / ) trachea and gallbladder, the
Cl secretory responses to nucleotide additions in the
P2Y2-R( / ) jejuna were not different from the wild type
mice (Fig. 6A). Like the
P2Y2-R(+/+) jejuna, approximately 25-30% of the
P2Y2-R( / ) jejuna failed to respond to any nucleotide
and were omitted from the data analyses. For the responders, the
potency of ATP and UTP and the magnitude of the Cl
secretory responses to these agonists in P2Y2-R( / ) mice
were virtually identical to those of the wild type mice (see Table III).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Mouse jejuna, P2Y2-R( / ).
A, Isc dose response to the indicated
nucleotides. n = 6 or more at each dose. B,
desensitization study of response to ATP, after pretreating tissue with
10 4 M UTP (n = 5).
None refers to ATP response without pretreatment with
another nucleotide (n = 5). p 0.05. C, desensitization study of response to UTP after
pretreating the tissue with ATP (10 4 M).
n = 8. None, n = 7. *,
p 0.05.
|
|
Like the P2Y2-R(+/+) jejuna, smaller responses to the
second triphosphate nucleotide were observed in the
P2Y2-R( / ) jejuna after the addition of a maximal dose
of a first triphosphate nucleotide (Fig. 6B). This
"desensitization" may reflect homologous desensitization of a novel
P2Y2-R-like receptor (see below), a ceiling effect, or
heterologous desensitization between an ATP and an UTP receptor. Since
pretreatment with the P2Y1-R antagonist A3P5P (30) was without effect on ADP/ATP responses (Fig.
7), it is unlikely that the persistent
ADP/ATP responses were mediated by P2Y1-R.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Lack of effect of P2Y1-R
antagonist (A3P5P) on jejunal Cl secretory responses to
adenine nucleotides. A, ATP response of
P2Y2-R( / ) jejuna in the presence and absence of A3P5P.
B, ADP response of P2Y2-R( / ) jejuna in the
presence and absence of A3P5P. All drugs were at a concentration of
10 4 M (n = 5 for each
point).
|
|
 |
DISCUSSION |
Numerous studies report that both purine and pyrimidine
triphosphate nucleotides regulate epithelial ion transport. Because the
P2Y2 receptor was the first receptor cloned that was
activated by both pyrimidine and purine nucleotides, many studies have
tentatively identified P2Y2-R as the receptor mediating
epithelial ion transport responses to triphosphate nucleotides. Based
on comparisons of Cl secretory responses in
P2Y2-R(+/+) and P2Y2-R( / ) mice, a
surprisingly wide spectrum in the P2Y2-R contribution to
ATP/UTP regulated ion transport was observed in the three different
epithelia studied. The contribution ranged from P2Y2-R,
being the dominant ATP/UTP receptor in tracheal epithelia, to the
gallbladder, where P2Y2-R appeared to transduce about 50%
of the triphosphate nucleotide responses, to the intestine, where
P2Y2-R appeared to transduce virtually none of the
triphosphate nucleotide actions.
These observations led to studies designed to identify the P2Y
receptors in addition to P2Y2-R that regulate ion transport in mouse epithelia. The following are candidate P2Y receptors that may
participate in this regulation, based on reports of studies of cloned
human P2 receptors: P2Y1, which has a rank order potency of
2-MeSADP > ADP > 2-MeSATP > ATP (10, 31, 32);
P2Y4, which is activated by UTP but not by ATP (15, 16),
P2Y6, which has a rank order of potency of UDP ADP
UTP/ATP (28, 33), and P2Y11-R, which has a rank order
potency of ATP > 2-MeSATP and is not activated by ADP, UDP, or
UTP (11). A problem, however, in assigning a response to these
previously characterized P2 receptors is that homologous murine P2
receptors have not been pharmacologically characterized in detail. For
instance, it is not known whether UDP is an agonist at the cloned mouse
P2Y2 receptor (34) and what is the rank order of potencies
for ATP and ADP at the cloned mouse P2Y1 receptor (32). The
importance of rodent data is highlighted by the recent report that the
rat P2Y4 receptor is activated equipotently by ATP and UTP
(35, 36).
Additional concerns in a pharmacological characterization of P2
receptor activity are data indicating that agonists may not be
receptor-specific. For example, , -meATP, which was originally thought be a specific and potent agonist for P2X receptors (37), is
only a relatively weak agonist at the P2X1 and
P2X3 receptors (38-40), while 2-MeSATP, which was
originally described as a selective P2Y (P2Y1) receptor
agonist (37), is a potent agonist at most P2X receptor subtypes (41).
The availability of mice with the P2Y2-R gene inactivated greatly
supplemented our pharmacological approaches to identification of the
roles of other P2Y receptors in nucleotide-mediated regulation of ion transport.
The concept of nucleotide-based pharmacotherapy for CF airways disease
has emphasized the importance of defining the specific purinoceptor
that mediates activation of Cl secretion in this tissue
(1). The data that describe the interactions between these ligands and
tracheal Cl secretory rates in wild type mice (Fig. 1)
demonstrate the difficulty in using strictly pharmacological approaches
(e.g. a combination of agonist dose-response curves and
desensitization protocols) to assign a specific P2Y receptor subtype to
an ion transport regulatory function. However, the combination of the
Cl secretion (Figs. 1 and 2) and
Ca2+i data from a companion paper (23) comparing
the wild type with P2Y2-R( / ) mice provide strong
evidence for the first definitive assignment of P2Y2-R to a
physiologic function. Thus, although costly and time-consuming, the
gene targeting technique appears to be the unique approach for
unambiguously defining P2Y2 receptor function in specific tissues.
There were small (~15% of P2Y2-R(+/+) responses)
residual ATP and UTP Cl secretory responses in the
P2Y2-R( / ) trachea as well as a small, persistent UDP
response. The detection of a relatively high potency UDP response
(EC50 of ~10 6 M, Table I) in
the P2Y2-R(+/+) mouse trachea and its persistence in the
P2Y2-R( / ) mouse suggest that a P2Y6
receptor mediated the UDP response. This observation is consistent with
recent evidence of the expression of a UDP receptor in human airway
epithelia (27). Data describing the equipotency of 2-MeSATP and ATP
(Table I), coupled with their cross-desensitization (Figs. 1 and 2), suggest that the P2Y1-R, a P2X-R, or the
P2Y11-R accounted for the very small residual ATP responses
in the P2Y2-R( / ) trachea. The results of intracellular
Ca2+ studies in the companion paper (23) favor
P2Y1-R as the "other" P2 receptor.
Investigations of purinoceptor regulation of gallbladder
Cl secretion have focused on triphosphate nucleotides
(17, 18, 42). In the wild type murine gallbladder, both ATP and UTP
were equipotent and effective agonists, consistent with a
P2Y2 receptor-mediated response (Fig. 3, Table II). The
effectiveness and potency of UDP was consistent with regulation of
Cl secretion in P2Y2-R(+/+) mouse gallbladder
by a P2Y6 receptor. An apparent major difference between
the gallbladder and the trachea is that 2-MeSATP or 2-MeSADP were
ineffective in gallbladder (Fig. 3), indicating that the
P2Y1 receptor (and P2Y11-R) are not
functionally expressed in this tissue.
The data from the P2Y2-R( / ) gallbladder indicate that
virtually all of the ATP regulation of Cl transport is
mediated via the P2Y2-R. These findings were further supported by the absence of effectiveness of P2Y1-R
agonists and adenosine. In contrast, about 70% of the UTP response
persisted. The cross-desensitization protocols with UDP and the potency
order UDP > UTP suggested, but do not prove, that both the
diphosphate and triphosphate pyrimidine nucleotide responses are
mediated by the P2Y6-R and point to the need for cloning
and characterizing the mouse P2Y6-R (as well as the mouse
P2Y4 receptor). These data suggest a role for released
pyrimidines as well as purines in the regulation of gallbladder ion
transport rates.
In wild type mice, the equipotency of ATP and UTP, coupled with the
partial cross-desensitization, suggested that the P2Y2-R transduced the Cl secretory responses to both purine and
pyrimidine triphosphate nucleotides in jejunal epithelium (Fig. 5). We
do not know why the potencies for all nucleotide agonists were shifted
to the right (Fig. 5 and 6), but we speculate that this shift could
reflect diffusion barriers, e.g. mucus, or high rates of
cell surface nucleotide catabolism. These data contrast with previous
studies in freshly excised rat and guinea pig intestines, which had
suggested a regulatory role of ATP, but not UTP, in ion transport (19, 43). However, the data from the P2Y2-R( / ) mouse
unequivocally established that these responses in mice were not
transduced by the P2Y2 receptor (Fig. 6; Table III). This
observation requires an analysis of other P2Y receptors that transduce
both purine and pyrimidine responses.
It appears unlikely that the UTP response is transduced by the
P2Y6 receptor, because UDP appeared to be a relatively
ineffective agonist in jejunal epithelium and the UTP responses were
brisk (Figs. 5 and 6). It is possible that UTP responses were
transduced by a P2Y4-like receptor. If the mouse
P2Y4-R exhibits a pharmacology similar to the rat
P2Y4 receptor (i.e. UTP = ATP), the
simplest hypothesis is that mouse jejunal ion transport is functionally regulated by ATP and UTP via P2Y4-R. Alternatively, if the
mouse P2Y4-R behaves like the human P2Y4-R,
i.e. UTP ATP, ATP and UTP might act on different
receptors, which cross-desensitize each other.
The effectiveness of ADP in stimulating jejunal Cl
secretion suggested the presence of a P2Y1 receptor.
However, it is unlikely that ADP (or ATP) was interacting with a
luminal P2Y1-R because of the failure of A3P5P to block
these responses (44). Moreover, previous reports indicating a
predominantly basolateral expression of P2Y1-R in other
epithelia (e.g. airways (45)) suggest that the
P2Y1 receptor was not involved in the Cl
responses to luminal ADP and ATP.
There is little precedent for an ADP-stimulated response not mediated
by the P2Y1 receptor. The most notable action of ADP on
receptors other than the P2Y1 receptor occurs in platelets. ADP-promoted platelet shape change and aggregation involves three independent receptors: the P2Y1 receptor, a P2X receptor,
and a yet unidentified receptor that couples to inhibition of adenylyl cyclase (46). In rat C6 glioma cells, ADP also potently promotes inhibition of adenylyl cyclase by a mechanism that is independent from
the P2Y1 receptor (10). Besides these observations, there are no obvious additional candidates other than novel P2 receptors to
mediate the jejunal response to ADP.
We conclude that the jejunal epithelium transduces Cl
secretory responses to luminal nucleotides by a quite different set of
receptors than are expressed on the tracheal or gallbladder epithelium.
The effectiveness of luminal ADP in stimulating jejunal Cl secretion had not been reported in gut epithelia
previously and was unique in the epithelia we surveyed. These
observations may have important implications for potential therapies
directed at this epithelium.
In summary, these studies of tissues excised from P2Y2
receptor deficient mice have identified a functional role for the
P2Y2 nucleotide receptor subtype in the regulation of ion
secretion. These studies have also demonstrated a diverse role for the
P2Y2-R in this activity, the contribution being dominant in
airways, intermediate in the gallbladder, and absent in the jejunum.
Further, by eliminating the P2Y2-R from tissues, the
studies have led to hypotheses that other P2Y receptor subtypes have
ion transport regulatory activities in these epithelia. For example, we
speculate that the P2Y6-R performs a relatively large
(gallbladder) and small (trachea) ion transport regulatory function in
some epithelia, whereas the P2Y4-like receptors are more
important in others, e.g. jejunum. Since airways presently
constitute the primary target for nucleotide therapy of CF (1) and
targeting a specific P2Y receptor subtype linked to Cl
secretion would appear to be an optimal strategy, these data support
the notion of the development of potent and selective agonists for the
P2Y2 receptor as potential therapies of CF lung disease and
expand the spectrum of receptor targets for other epithelia.
 |
FOOTNOTES |
*
This study was supported by National Institutes of Health
Grants HL34322 and DK51791 and Cystic Fibrosis Foundation Grant R026.
To whom correspondence should be addressed: Cystic
Fibrosis/Pulmonary Research and Treatment Center, University of North
Carolina, Chapel Hill, NC 27599. Tel.: 919-966-5602; Fax:
919-966-7524.
2
B. R. Grubb, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
CF, cystic fibrosis;
CFTR, cystic fibrosis transmembrane conductance regulator;
Isc, short circuit current;
A3P5P, adenosine
3',5'-diphosphate;
, -meATP, , -methylene adenosine
5'-triphosphate;
2-MeSATP, 2-methylthioadenosine 5'-triphosphate;
2-MeSADP, 2 methylthioadenosine 5'-diphosphate, EC50, 50%
of maximal effective concentration.
 |
REFERENCES |
| 1.
|
Donaldson, S. H.,
and Boucher, R. C.
(1998)
in
The P2 Nucleotide Receptors
(Turner, J. T.
, Weisman, G. A.
, and Fedan, J. S., eds)
, pp. 413-424, Humana Press, Totowa, NJ
|
| 2.
|
Davis, P. B.,
Drumm, M.,
and Konstan, M. W.
(1996)
Am. J. Respir. Crit. Care Med.
154,
1229-1256[Medline]
[Order article via Infotrieve]
|
| 3.
|
Fredholm, B. B.,
Abbracchio, M. P.,
Burnstock, G.,
Dubyak, G. R.,
Harden, T. K.,
Jacobson, K. A.,
Schwabe, U.,
and Williams, M.
(1997)
Trends Pharmacol. Sci.
18,
79-82[Medline]
[Order article via Infotrieve]
|
| 4.
|
Devor, D. C.,
and Pilewski, J. M.
(1999)
Am. J. Physiol.
276,
C827-C837
|
| 5.
|
Clarke, L. L.,
and Boucher, R. C.
(1992)
Am. J. Physiol.
263,
C348-C356[Abstract/Free Full Text]
|
| 6.
|
Clarke, L. L.,
Chinet, T.,
and Boucher, R. C.
(1997)
Am. J. Physiol.
272,
L1084-L1091[Abstract/Free Full Text]
|
| 7.
|
Brown, H. A.,
Lazarowski, E. R.,
Boucher, R. C.,
and Harden, T. K.
(1991)
Mol. Pharmacol.
40,
648-655[Abstract]
|
| 8.
|
Parr, C. E.,
Sullivan, D. M.,
Paradiso, A. M.,
Lazarowski, E. R.,
Burch, L. H.,
Olsen, J. C.,
Erb, L.,
Weisman, G. A.,
Boucher, R. C.,
and Turner, J. T.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3275-3279[Abstract/Free Full Text]
|
| 9.
|
Janssens, R.,
Communi, D.,
Pirotton, S.,
Samson, M.,
Parmentier, M.,
and Boeynaems, J.-M.
(1996)
Biochem. Biophys. Res. Commun.
221,
588-593[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Schachter, J. B.,
Li, Q.,
Boyer, J. L.,
Nicholas, R. A.,
and Harden, T. K.
(1996)
Br. J. Pharmacol.
118,
167-173[Medline]
[Order article via Infotrieve]
|
| 11.
|
Communi, D.,
Govaerts, C.,
Parmentier, M.,
and Boeynaems, J. M.
(1997)
J. Biol. Chem.
272,
31969-31973[Abstract/Free Full Text]
|
| 12.
|
Soto, F.,
Garcia-Guzman, M.,
and Stuhmer, W.
(1997)
J. Membr. Biol.
160,
91-100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Humphrey, P. P.,
Buell, G.,
Kennedy, I.,
Khakh, B. S.,
Michel, A. D.,
Surprenant, A.,
and Trezise, D. J.
(1995)
Naunyn Schmiedebergs Arch. Pharmacol.
352,
585-596[Medline]
[Order article via Infotrieve]
|
| 14.
|
Surprenant, A.
(1996)
Ciba Found. Symp.
198,
208-222[Medline]
[Order article via Infotrieve]
|
| 15.
|
Communi, D.,
Pirotton, S.,
Parmentier, M.,
and Boeynaems, J.-M.
(1995)
J. Biol. Chem.
270,
30849-30852[Abstract/Free Full Text]
|
| 16.
|
Nguyen, T.,
Erb, L.,
Weisman, G. A.,
Marchese, A.,
Heng, H. H. Q.,
Garrad, R. C.,
George, S. R.,
Turner, J. T.,
and O'Dowd, B. F.
(1995)
J. Biol. Chem.
270,
30845-30848[Abstract/Free Full Text]
|
| 17.
|
Harline, M. C.,
Price, E. M.,
Glover, G. G.,
Garrad, R. C.,
Weisman, G. A.,
Turner, J. T.,
and Clarke, L. L.
(1996)
Pediatr. Pulmonol., Suppl.
13,
284-285 (abstr.)
|
| 18.
|
Glover, G. G.,
Harline, M. C.,
Ortero, M.,
Camden, J. M.,
Turner, J. T.,
Weisman, G. A.,
and Clarke, L. L.
(1996)
Pediatr. Pulmonol., Suppl.
13,
285 (abstr.)
|
| 19.
|
Kohn, P. G.,
Newey, H.,
and Smyth, D. H.
(1970)
J. Physiol. (Lond.)
208,
203-220[Abstract/Free Full Text]
|
| 20.
|
Inoue, C. N.,
Woo, J. S.,
Schwiebert, E. M.,
Morita, T.,
Hanaoka, K.,
Guggino, S. E.,
and Guggino, W. B.
(1997)
Am. J. Physiol.
272,
C1862-C1870[Abstract/Free Full Text]
|
| 21.
|
Koller, B. H.,
and Smithies, O.
(1992)
Annu. Rev. Immunol.
10,
705-730[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Mason, S. J.,
Paradiso, A. M.,
and Boucher, R. C.
(1991)
Br. J. Pharmacol.
103,
1649-1656[Medline]
[Order article via Infotrieve]
|
| 23.
|
Homolya, L.,
Watt, W. C.,
Lazarowski, E. R.,
Koller, B. H.,
and Boucher, R. C.
(1999)
J. Biol. Chem.
274,
26454-26460[Abstract/Free Full Text]
|
| 24.
|
Grubb, B. R.,
Paradiso, A. M.,
and Boucher, R. C.
(1994)
Am. J. Physiol.
267,
C293-C300[Abstract/Free Full Text]
|
| 25.
|
Grubb, B. R.
(1995)
Am. J. Physiol.
268,
G505-G513[Abstract/Free Full Text]
|
| 26.
|
Grubb, B. R.,
Vick, R. N.,
and Boucher, R. C.
(1994)
Am. J. Physiol.
266,
C1478-C1483[Abstract/Free Full Text]
|
| 27.
|
Lazarowski, E. R.,
Paradiso, A. M.,
Watt, W. C.,
Harden, T. K.,
and Boucher, R. C.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2599-2603[Abstract/Free Full Text]
|
| 28.
|
Nicholas, R. A.,
Watt, W. C.,
Lazarowski, E. R.,
Li, Q.,
and Harden, T. K.
(1996)
Mol. Pharmacol.
50,
224-229[Abstract]
|
| 29.
|
Chang, K.,
Hanaoka, K.,
Kumada, M.,
and Takuwa, Y.
(1995)
J. Biol. Chem.
270,
26152-26158[Abstract/Free Full Text]
|
| 30.
|
Boyer, J. L.,
Romero-Avila, T.,
Schachter, J. B.,
and Harden, T. K.
(1996)
Mol. Pharmacol.
50,
1323-1329[Abstract]
|
| 31.
|
Palmer, R. K.,
Boyer, J. L.,
Schachter, J. B.,
Nicholas, R. A.,
and Harden, T. K.
(1998)
Mol. Pharmacol.
54,
1118-1123[Abstract/Free Full Text]
|
| 32.
|
Tokuyama, Y.,
Hara, M.,
Jones, E. M. C.,
Fan, Z.,
and Bell, G. I.
(1995)
Biochem. Biophys. Res. Commun.
211,
211-218[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Communi, D.,
Motte, S.,
Boeynaems, J. M.,
and Pirotton, S.
(1996)
Eur. J. Pharmacol.
317,
383-389[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Lustig, K. D.,
Shiau, A. K.,
Brake, A. J.,
and Julius, D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5113-5117[Abstract/Free Full Text]
|
| 35.
|
Webb, T. E.,
Henderson, D. J.,
Roberts, J. A.,
and Barnard, E. A.
(1998)
J. Neurochem.
71,
1348-1357[Medline]
[Order article via Infotrieve]
|
| 36.
|
Bogdanov, Y. D.,
Wildman, S. S.,
Clements, M. P.,
King, B. F.,
and Burnstock, G.
(1998)
Br. J. Pharmacol.
124,
428-430[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Burnstock, G.,
and Kennedy, C.
(1985)
Gen. Pharmacol.
16,
433-440[Medline]
[Order article via Infotrieve]
|
| 38.
|
Valera, S.,
Hussy, N.,
Evans, R. J.,
Adami, N.,
North, R. A.,
Surprenant, A.,
and Buell, G.
(1994)
Nature
371,
516-519[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Chen, C. C.,
Akopian, A. N.,
Sivilotti, L.,
Colquhoun, D.,
Burnstock, G.,
and Wood, J. N.
(1995)
Nature
377,
428-431[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Lewis, C.,
Neidhart, S.,
Holy, C.,
North, R. A.,
Buell, G.,
and Surprenant, A.
(1995)
Nature
377,
432-435[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Evans, R. J.,
Surprenant, A.,
and North, R. A.
(1998)
in
The P2 Nucleotide Receptors
(Turner, J. T.
, Weisman, G. A.
, and Fedan, J. S., eds)
, pp. 43-61, Humana Press, Totowa, NJ
|
| 42.
|
Cotton, C. U.,
and Reuss, L.
(1991)
J. Gen. Physiol.
97,
949-971[Abstract/Free Full Text]
|
| 43.
|
Korman, L. Y.,
Lemp, G. F.,
Jackson, M. J.,
and Gardner, J. D.
(1982)
Biochim. Biophys. Acta
721,
47-54[Medline]
[Order article via Infotrieve]
|
| 44.
|
Boyer, J. L.,
Mohanram, A.,
Camaioni, E.,
Jacobson, K. A.,
and Harden, T. K.
(1998)
Br. J. Pharmacol.
124,
1-3[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Homolya, L.,
Grubb, B. R.,
Lazarowski, E. R.,
Boucher, R. C.,
and Koller, B. H.
(1997)
Pediatr. Pulmonol., Suppl.
14,
234 (abstr.)
|
| 46.
|
Jin, J.,
Daniel, J. L.,
and Kunapuli, S. P.
(1998)
J. Biol. Chem.
273,
2030-2034[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Zhang, J. M. Sands, D. E. Kohan, R. D. Nelson, C. F. Martin, N. G. Carlson, C. D. Kamerath, Y. Ge, J. D. Klein, and B. K. Kishore
Potential role of purinergic signaling in urinary concentration in inner medulla: insights from P2Y2 receptor gene knockout mice
Am J Physiol Renal Physiol,
December 1, 2008;
295(6):
F1715 - F1724.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E. Wolk, E. R. Lazarowski, Z. P. Traylor, E. N. Z. Yu, N. A. Jewell, R. K. Durbin, J. E. Durbin, and I. C. Davis
Influenza A Virus Inhibits Alveolar Fluid Clearance in BALB/c Mice
Am. J. Respir. Crit. Care Med.,
November 1, 2008;
178(9):
969 - 976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Bar, P.-J. Guns, J. Metallo, D. Cammarata, F. Wilkin, J.-M. Boeynams, H. Bult, and B. Robaye
Knockout Mice Reveal a Role for P2Y6 Receptor in Macrophages, Endothelial Cells, and Vascular Smooth Muscle Cells
Mol. Pharmacol.,
September 1, 2008;
74(3):
777 - 784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Keating and L.R. Quinlan
Effect of Basolateral Adenosine Triphosphate on Chloride Secretion by Bovine Oviductal Epithelium
Biol Reprod,
June 1, 2008;
78(6):
1119 - 1126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Vallon
P2 receptors in the regulation of renal transport mechanisms
Am J Physiol Renal Physiol,
January 1, 2008;
294(1):
F10 - F27.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Rieg, R. A. Bundey, Y. Chen, G. Deschenes, W. Junger, P. A. Insel, and V. Vallon
Mice lacking P2Y2 receptors have salt-resistant hypertension and facilitated renal Na+ and water reabsorption
FASEB J,
November 1, 2007;
21(13):
3717 - 3726.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ehre, Y. Zhu, L. H. Abdullah, J. Olsen, K. I. Nakayama, K. Nakayama, R. O. Messing, and C. W. Davis
nPKC{varepsilon}, a P2Y2-R downstream effector in regulated mucin secretion from airway goblet cells
Am J Physiol Cell Physiol,
November 1, 2007;
293(5):
C1445 - C1454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. R. Orriss, J. C. Utting, A. Brandao-Burch, K. Colston, B. R. Grubb, G. Burnstock, and T. R. Arnett
Extracellular Nucleotides Block Bone Mineralization in Vitro: Evidence for Dual Inhibitory Mechanisms Involving Both P2Y2 Receptors and Pyrophosphate
Endocrinology,
September 1, 2007;
148(9):
4208 - 4216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. F. Bush, S. V. Jones, A. N. Lyle, K. P. Minneman, K. J. Ressler, and R. A. Hall
Specificity of Olfactory Receptor Interactions with Other G Protein-coupled Receptors
J. Biol. Chem.,
June 29, 2007;
282(26):
19042 - 19051.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Button, M. Picher, and R. C. Boucher
Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia
J. Physiol.,
April 15, 2007;
580(2):
577 - 592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Douillet, W. P. Robinson III, P. M. Milano, R. C. Boucher, and P. B. Rich
Nucleotides induce IL-6 release from human airway epithelia via P2Y2 and p38 MAPK-dependent pathways
Am J Physiol Lung Cell Mol Physiol,
October 1, 2006;
291(4):
L734 - L746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al.
International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy
Pharmacol. Rev.,
September 1, 2006;
58(3):
281 - 341.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. McNamara, M. Gallup, A. Sucher, I. Maltseva, D. McKemy, and C. Basbaum
AsialoGM1 and TLR5 Cooperate in Flagellin-Induced Nucleotide Signaling to Activate Erk1/2
Am. J. Respir. Cell Mol. Biol.,
June 1, 2006;
34(6):
653 - 660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Arthur, S. Georgi, K. Akassoglou, and P. A. Insel
Inhibition of apoptosis by P2Y2 receptor activation: novel pathways for neuronal survival.
J. Neurosci.,
April 5, 2006;
26(14):
3798 - 3804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. C. Davis, E. R. Lazarowski, J. M. Hickman-Davis, J. A. Fortenberry, F.-P. Chen, X. Zhao, E. Sorscher, L. M. Graves, W. M. Sullender, and S. Matalon
Leflunomide Prevents Alveolar Fluid Clearance Inhibition by Respiratory Syncytial Virus
Am. J. Respir. Crit. Care Med.,
March 15, 2006;
173(6):
673 - 682.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ferrari, A. la Sala, E. Panther, J. Norgauer, F. Di Virgilio, and M. Idzko
Activation of human eosinophils via P2 receptors: novel findings and future perspectives
J. Leukoc. Biol.,
January 1, 2006;
79(1):
7 - 15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Arthur, K. Akassoglou, and P. A. Insel
P2Y2 receptor activates nerve growth factor/TrkA signaling to enhance neuronal differentiation
PNAS,
December 27, 2005;
102(52):
19138 - 19143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Geary, H. Akinbi, T. Korfhagen, J.-E. Fabre, R. Boucher, and W. Rice
Increased susceptibility of purinergic receptor-deficient mice to lung infection with Pseudomonas aeruginosa
Am J Physiol Lung Cell Mol Physiol,
November 1, 2005;
289(5):
L890 - L895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.-D. Qi, S. C. Wolff, and R. A. Nicholas
The Apical Targeting Signal of the P2Y2 Receptor Is Located in Its First Extracellular Loop
J. Biol. Chem.,
August 12, 2005;
280(32):
29169 - 29175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E Matos, B Robaye, J. M Boeynaems, R Beauwens, and J Leipziger
K+ secretion activated by luminal P2Y2 and P2Y4 receptors in mouse colon
J. Physiol.,
April 1, 2005;
564(1):
269 - 279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Wolff, A.-D. Qi, T. K. Harden, and R. A. Nicholas
Polarized expression of human P2Y receptors in epithelial cells from kidney, lung, and colon
Am J Physiol Cell Physiol,
March 1, 2005;
288(3):
C624 - C632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Bucheimer and J. Linden
Purinergic regulation of epithelial transport
J. Physiol.,
March 1, 2004;
555(2):
311 - 321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Li, X. Luo, W. Zeng, and S. Muallem
Cell-specific Behavior of P2X7 Receptors in Mouse Parotid Acinar and Duct Cells
J. Biol. Chem.,
November 28, 2003;
278(48):
47554 - 47561.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Marteau, E. Le Poul, D. Communi, D. Communi, C. Labouret, P. Savi, J.-M. Boeynaems, and N. S. Gonzalez
Pharmacological Characterization of the Human P2Y13 Receptor
Mol. Pharmacol.,
July 1, 2003;
64(1):
104 - 112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Joseph, M. R. Buchakjian, and G. R. Dubyak
Colocalization of ATP Release Sites and Ecto-ATPase Activity at the Extracellular Surface of Human Astrocytes
J. Biol. Chem.,
June 20, 2003;
278(26):
23331 - 23342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sak, J.-M. Boeynaems, and H. Everaus
Involvement of P2Y receptors in the differentiation of haematopoietic cells
J. Leukoc. Biol.,
April 1, 2003;
73(4):
442 - 447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. R. Dubyak
Knock-Out Mice Reveal Tissue-Specific Roles of P2Y Receptor Subtypes in Different Epithelia
Mol. Pharmacol.,
April 1, 2003;
63(4):
773 - 776.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Robaye, E. Ghanem, F. Wilkin, D. Fokan, W. Van Driessche, S. Schurmans, J.-M. Boeynaems, and R. Beauwens
Loss of Nucleotide Regulation of Epithelial Chloride Transport in the Jejunum of P2Y4-Null Mice
Mol. Pharmacol.,
April 1, 2003;
63(4):
777 - 783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Leipziger
Control of epithelial transport via luminal P2 receptors
Am J Physiol Renal Physiol,
March 1, 2003;
284(3):
F419 - F432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Vial and R. J. Evans
P2X1 Receptor-Deficient Mice Establish the Native P2X Receptor and a P2Y6-Like Receptor in Arteries
Mol. Pharmacol.,
December 1, 2002;
62(6):
1438 - 1445.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Koval
Sharing signals: connecting lung epithelial cells with gap junction channels
Am J Physiol Lung Cell Mol Physiol,
November 1, 2002;
283(5):
L875 - L893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yamamoto and Y. Suzuki
Role of luminal ATP in regulating electrogenic Na+ absorption in guinea pig distal colon
Am J Physiol Gastrointest Liver Physiol,
August 1, 2002;
283(2):
G300 - G308.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Donaldson, M. Picher, and R. C. Boucher
Secreted and Cell-Associated Adenylate Kinase and Nucleoside Diphosphokinase Contribute to Extracellular Nucleotide Metabolism on Human Airway Surfaces
Am. J. Respir. Cell Mol. Biol.,
February 1, 2002;
26(2):
209 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lehrmann, J. Thomas, S. J. Kim, C. Jacobi, and J. Leipziger
Luminal P2Y2 Receptor-Mediated Inhibition of Na+ Absorption in Isolated Perfused Mouse CCD
J. Am. Soc. Nephrol.,
January 1, 2002;
13(1):
10 - 18.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kunzelmann and M. Mall
Electrolyte Transport in the Mammalian Colon: Mechanisms and Implications for Disease
Physiol Rev,
January 1, 2002;
82(1):
245 - 289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Chen, Y. H. Zhao, and R. Wu
Differential Regulation of Airway Mucin Gene Expression and Mucin Secretion by Extracellular Nucleotide Triphosphates
Am. J. Respir. Cell Mol. Biol.,
October 1, 2001;
25(4):
409 - 417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Dranoff, A. I. Masyuk, E. A. Kruglov, N. F. LaRusso, and M. H. Nathanson
Polarized expression and function of P2Y ATP receptors in rat bile duct epithelia
Am J Physiol Gastrointest Liver Physiol,
October 1, 2001;
281(4):
G1059 - G1067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Grubb, A. J. Pace, E. Lee, B. H. Koller, and R. C. Boucher
Alterations in airway ion transport in NKCC1-deficient mice
Am J Physiol Cell Physiol,
August 1, 2001;
281(2):
C615 - C623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. BAILEY, M. IMBERT-TEBOUL, C. TURNER, S. K. SRAI, G. BURNSTOCK, and R. J. UNWIN
Evidence for Basolateral P2Y6 Receptors along the Rat Proximal Tubule: Functional and Molecular Characterization
J. Am. Soc. Nephrol.,
August 1, 2001;
12(8):
1640 - 1647.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. McNamara, A. Khong, D. McKemy, M. Caterina, J. Boyer, D. Julius, and C. Basbaum
ATP transduces signals from ASGM1, a glycolipid that functions as a bacterial receptor
PNAS,
July 31, 2001;
98(16):
9086 - 9091.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Gillie, A. J. Pace, R. J. Coakley, B. H. Koller, and P. M. Barker
Liquid and Ion Transport by Fetal Airway and Lung Epithelia of Mice Deficient in Sodium-Potassium-2-Chloride Transporter
Am. J. Respir. Cell Mol. Biol.,
July 1, 2001;
25(1):
14 - 20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Smitham and K. E. Barrett
Differential effects of apical and basolateral uridine triphosphate on intestinal epithelial chloride secretion
Am J Physiol Cell Physiol,
June 1, 2001;
280(6):
C1431 - C1439.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Morse, J. L. Smullen, and C. W. Davis
Differential effects of UTP, ATP, and adenosine on ciliary activity of human nasal epithelial cells
Am J Physiol Cell Physiol,
June 1, 2001;
280(6):
C1485 - C1497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. W. Inscho
P2 receptors in regulation of renal microvascular function
Am J Physiol Renal Physiol,
June 1, 2001;
280(6):
F927 - F944.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. F. Brosnan, E. Scemes, and D. C. Spray
Cytokine Regulation of Gap Junction Connectivity : An Open-and-Shut Case or Changing Partners at the Nexus?
Am. J. Pathol.,
May 1, 2001;
158(5):
1565 - 1569.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. R. Lazarowski, L. G. Rochelle, W. K. O'Neal, C. M. P. Ribeiro, B. R. Grubb, V. Zhang, T. K. Harden, and R. C. Boucher
Cloning and Functional Characterization of Two Murine Uridine Nucleotide Receptors Reveal a Potential Target for Correcting Ion Transport Deficiency in Cystic Fibrosis Gallbladder
J. Pharmacol. Exp. Ther.,
April 1, 2001;
297(1):
43 - 49.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. R. Lazarowski and R. C. Boucher
UTP as an Extracellular Signaling Molecule
Physiology,
February 1, 2001;
16(1):
1 - 5.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Burnstock and M. Williams
P2 Purinergic Receptors: Modulation of Cell Function and Therapeutic Potential
J. Pharmacol. Exp. Ther.,
December 1, 2000;
295(3):
862 - 869.
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Mall, A. Wissner, T. Gonska, D. Calenborn, J. Kuehr, M. Brandis, and K. Kunzelmann
Inhibition of Amiloride-Sensitive Epithelial Na+ Absorption by Extracellular Nucleotides in Human Normal and Cystic Fibrosis Airways
Am. J. Respir. Cell Mol. Biol.,
December 1, 2000;
23(6):
755 - 761.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. DEETJEN, J. THOMAS, H. LEHRMANN, S. J. KIM, and J. LEIPZIGER
The Luminal P2Y Receptor in the Isolated Perfused Mouse Cortical Collecting Duct
J. Am. Soc. Nephrol.,
October 1, 2000;
11(10):
1798 - 1806.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
L. Homolya, T. H. Steinberg, and R. C. Boucher
Cell to Cell Communication in Response to Mechanical Stress via Bilateral Release of ATP and UTP in Polarized Epithelia
J. Cell Biol.,
September 18, 2000;
150(6):
1349 - 1360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Dranoff, A. F. O'Neill, A. M. Franco, S.-Y. Cai, G. C. Connolly, N. Ballatori, J. L. Boyer, and M. H. Nathanson
A Primitive ATP Receptor from the Little Skate Raja erinacea
J. Biol. Chem.,
September 22, 2000;
275(39):
30701 - 30706.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|